About this course

Learning Objectives

• Describe the bidirectional relationship between obesity & mental health, including ADHD, anxiety, depression, bipolar disorder, & schizophrenia
• Recognize weight-promoting psychotropic medications and strategies to minimize metabolic impact through medication selection and interdisciplinary care.
• Apply evidence-based lifestyle and behavioral strategies with an appreciation of the biological and psychological realities faced by patients living with obesity.
• Discuss modern obesity medications, including mechanisms, side-effect profiles, and considerations relevant to behavioral health practice.

Learning Levels

• Beginner

Target Audience

Course Instructor(s)

• 

  Richele L. Corrado, DO, MPH, FACP, DABOM

  Richele Corrado, a former Navy physician, is a board-certified Internist, Obesity Medicine Specialist, and Medical Director at Revolution Medicine, Health & Fitness. She is the former Director of the Comprehensive Weight Management Program and Internal Medicine Residency Associate Program Director at Walter Reed National Military Medical Center. She has been instrumental in expanding education and access to treatment within the Department of Defense (DOD), including advocating for active-duty service members' access to obesity medications. She co-led the 2025 VA/DOD Obesity Clinical Practice Guideline update and serves as co-chair of The Obesity Society's Policy and Advocacy Committee as well as the co-chair of the Obesity Medicine Association Obesity Algorithm Workgroup. She has delivered over 50 regional, national, and international presentations and developed obesity and leadership curricula for providers and trainees nationwide. Her work has earned numerous accolades, including Walter Reed’s 2023 Department of Medicine Civilian Provider of the Year, Associate Master Clinician, Walter Reed's 2022 Graduate Medical Education Faculty Mentor of the Year, and Walter Reed's IM residency program's Faculty Teacher of the Year in 2024. She is a Clinical Associate Professor of Medicine at the Uniformed Services University where she teaches medicine and nursing students about obesity, and she is a member of the Gold Humanism Honor Society.

References

• Carolan, A., Hynes-Ryan, C., Agarwal, S. M., Bourke, R., Cullen, W., Gaughran, F., ... & O’Donoghue, B. (2025). Metformin for the prevention of antipsychotic-induced weight gain: guideline development and consensus validation. Schizophrenia Bulletin, 51(5), 1193-1205
• Lores, T., Musker, M., Collins, K., Burke, A., Perry, S. W., Wong, M. L., & Licinio, J. (2020). Pilot trial of a group cognitive behavioural therapy program for comorbid depression and obesity. BMC psychology, 8(1), 34.
• McIntyre, R. S., Kwan, A. T., Rosenblat, J. D., Teopiz, K. M., & Mansur, R. B. (2024). Psychotropic drug–related weight gain and its treatment. American Journal of Psychiatry, 181(1), 26-38.
• Mulugeta, A., Zhou, A., Power, C., & Hyppönen, E. (2018). Obesity and depressive symptoms in mid-life: a population-based cohort study. BMC psychiatry, 18(1), 297.
• Tak YJ, Lee SY. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? Curr Obes Rep. 2021 Mar;10(1):14-30. doi: 10.1007/s13679-020-00422-w. Epub 2021 Jan 6. PMID: 33410104; PMCID: PMC7787121.
• Pierret, A. C. S., Mizuno, Y., Saunders, P., Lim, E., De Giorgi, R., Howes, O. D., McCutcheon, R. A., McGowan, B., Sen Gupta, P., Smith, D., Ismail, K., & Pillinger, T. (2025). Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis. JAMA psychiatry, 82(7), 643–653. https://doi.org/10.1001/jamapsychiatry.2025.0679